Trial Profile
A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2022
Price :
$35
*
At a glance
- Drugs Tafasitamab (Primary) ; Idelalisib; Venetoclax
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms COSMOS
- Sponsors MorphoSys
- 10 Dec 2021 Status changed from active, no longer recruiting to completed.
- 29 Oct 2020 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 06 Nov 2019 Results of primary analysis for both cohorts released in the 61st Annual Meeting and Exposition of the American Society of Hematology.